These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 36741022)

  • 1. Ground glass opacity resection extent assessment trial
    Li H; Wang Y; Chen Y; Zhong C; Fang W
    Front Oncol; 2023; 13():1052796. PubMed ID: 36741022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What Do We Talk About Now When We Talk About Segmentectomy for GGO?
    Li H; Shen C; Chen Y; Wang Y; Zhong C; Fang W
    Front Surg; 2022; 9():831246. PubMed ID: 35242804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Segmentectomy versus lobectomy for ground-glass opacity dominant cT1N0 invasive lung adenocarcinoma.
    Ma Z; Zhang Y; Han H; Wang S; Li Y; Chen H
    Transl Lung Cancer Res; 2024 Jun; 13(6):1201-1209. PubMed ID: 38973943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Appropriate sublobar resection choice for ground glass opacity-dominant clinical stage IA lung adenocarcinoma: wedge resection or segmentectomy.
    Tsutani Y; Miyata Y; Nakayama H; Okumura S; Adachi S; Yoshimura M; Okada M
    Chest; 2014 Jan; 145(1):66-71. PubMed ID: 24551879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncologic outcomes of segmentectomy compared with lobectomy for clinical stage IA lung adenocarcinoma: propensity score-matched analysis in a multicenter study.
    Tsutani Y; Miyata Y; Nakayama H; Okumura S; Adachi S; Yoshimura M; Okada M
    J Thorac Cardiovasc Surg; 2013 Aug; 146(2):358-64. PubMed ID: 23477694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial.
    Aokage K; Suzuki K; Saji H; Wakabayashi M; Kataoka T; Sekino Y; Fukuda H; Endo M; Hattori A; Mimae T; Miyoshi T; Isaka M; Yoshioka H; Nakajima R; Nakagawa K; Okami J; Ito H; Kuroda H; Tsuboi M; Okumura N; Takahama M; Ohde Y; Aoki T; Tsutani Y; Okada M; Watanabe SI;
    Lancet Respir Med; 2023 Jun; 11(6):540-549. PubMed ID: 36893780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should resection extent be decided by total lesion size or solid component size in ground glass opacity-containing lung adenocarcinomas?
    Lin B; Wang R; Chen L; Gu Z; Ji C; Fang W
    Transl Lung Cancer Res; 2021 Jun; 10(6):2487-2499. PubMed ID: 34295656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic effect of ground-glass opacity in subcentimeter invasive lung adenocarcinoma.
    Bai J; Fu F; Sun W; Deng C; Ma Z; Wang S; Deng L; Zhang Y; Chen H
    J Thorac Dis; 2023 Apr; 15(4):1559-1571. PubMed ID: 37197537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of Pathologic Tumor Invasion and Prognosis for Ground Glass Opacity Featured Lung Adenocarcinoma.
    Ye T; Deng L; Xiang J; Zhang Y; Hu H; Sun Y; Li Y; Shen L; Wang S; Xie L; Chen H
    Ann Thorac Surg; 2018 Dec; 106(6):1682-1690. PubMed ID: 30096292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognosis of invasive adenocarcinoma presenting as ground-glass opacity on chest computed tomography after sublobar resection.
    Moon Y; Lee KY; Park JK
    J Thorac Dis; 2017 Oct; 9(10):3782-3792. PubMed ID: 29268386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [JCOG lung cancer surgery trial series: review and interpretation].
    Li RZ; Qiu B
    Zhonghua Zhong Liu Za Zhi; 2022 Jul; 44(7):703-711. PubMed ID: 35880335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct Clinicopathologic Characteristics and Prognosis Based on the Presence of Ground Glass Opacity Component in Clinical Stage IA Lung Adenocarcinoma.
    Hattori A; Hirayama S; Matsunaga T; Hayashi T; Takamochi K; Oh S; Suzuki K
    J Thorac Oncol; 2019 Feb; 14(2):265-275. PubMed ID: 30368010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical Outcomes of Lobectomy Versus Limited Resection for Clinical Stage I Ground-Glass Opacity Lung Adenocarcinoma 2 Centimeters or Smaller.
    Zhang C; He Z; Cheng J; Cao J; Hu J
    Clin Lung Cancer; 2021 Mar; 22(2):e160-e168. PubMed ID: 33160898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncologic outcomes of segmentectomy for stage IA radiological solid-predominant lung cancer >2 cm in maximum tumour size.
    Hattori A; Matsunaga T; Fukui M; Takamochi K; Oh S; Suzuki K
    Interact Cardiovasc Thorac Surg; 2022 Nov; 35(6):. PubMed ID: 36161317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protocol for a single-arm, multicenter, prospective, confirmatory phase III trial of wedge resection for invasive ground glass opacity-featured lung cancer with a size ≤2 cm and a consolidation tumor ratio between 0.25 and 0.5 (ECTOP-1020 study).
    Li T; Fu F; Zhang Y; Chen H
    J Thorac Dis; 2024 Jul; 16(7):4711-4718. PubMed ID: 39144343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical Outcomes of Radiographically Noninvasive Lung Adenocarcinoma according to Surgical Strategy: Wedge Resection, Segmentectomy, and Lobectomy.
    Ha KJ; Yun JK; Lee GD; Cho WC; Choi SH; Kim HR; Kim YH; Kim DK; Park SI
    Korean J Thorac Cardiovasc Surg; 2018 Dec; 51(6):376-383. PubMed ID: 30588445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Segmentectomy versus lobectomy for small-sized pure solid non-small cell lung cancer.
    Li Z; Xu W; Pan X; Wu W; Chen L
    Thorac Cancer; 2023 Apr; 14(11):1021-1028. PubMed ID: 36882365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A non-randomized confirmatory trial of segmentectomy for clinical T1N0 lung cancer with dominant ground glass opacity based on thin-section computed tomography (JCOG1211).
    Aokage K; Saji H; Suzuki K; Mizutani T; Katayama H; Shibata T; Watanabe S; Asamura H;
    Gen Thorac Cardiovasc Surg; 2017 May; 65(5):267-272. PubMed ID: 28255781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of ground-glass opacity in pure invasive and lepidic component in pure solid lung adenocarcinoma for predicting aggressiveness.
    Mimae T; Miyata Y; Tsutani Y; Shimada Y; Ito H; Nakayama H; Ikeda N; Okada M
    JTCVS Open; 2022 Sep; 11():300-316. PubMed ID: 36172403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Segmentectomy for clinical stage IA lung adenocarcinoma showing solid dominance on radiology.
    Tsutani Y; Miyata Y; Nakayama H; Okumura S; Adachi S; Yoshimura M; Okada M
    Eur J Cardiothorac Surg; 2014 Oct; 46(4):637-42. PubMed ID: 24477740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.